The courtroom clock in Missouri has been reset. Bayer’s final hearing to approve the $7.25 billion glyphosate class-action settlement — originally slated for August 19 — will now take place on September 10, after the company requested a postponement to process a fresh wave of opt-outs from plaintiffs seeking to exit the agreement. The delay follows a landmark US Supreme Court decision in the Durnell case, handed down in late June, in which the justices ruled 7-2 that federal law preempts certain state-level failure-to-warn claims when the EPA has approved a product’s labeling. For Bayer, the ruling represents a meaningful shift in the legal terrain: plaintiffs are now reassessing whether to remain in the settlement pool, and the company’s management believes the new jurisprudence strengthens its hand in negotiations.
The timing of the legal calendar is hardly ideal for a company that would prefer to close this chapter, but the operational story Bayer delivered on Tuesday gives investors a more immediate reason for optimism. Revenue rose 2.2 percent on a currency- and portfolio-adjusted basis to €10.872 billion in the second quarter, while adjusted EBITDA advanced 1.9 percent to €2.144 billion. The bottom line swung back into positive territory with a net profit of €219 million, reversing a €199 million loss in the year-earlier period. Adjusted earnings per share, however, declined 16.7 percent to €0.95.
The engine behind the quarter was Crop Science, the agriculture division that has been the epicenter of the glyphosate litigation. Segment EBITDA surged 30.2 percent to €902 million, propelled by efficiency programs and robust US demand for Dicamba seeds. The pharmaceuticals business, by contrast, remained a laggard: declining sales of the blockbuster anticoagulant Xarelto dragged segment earnings down 3.6 percent.
The balance sheet also received meaningful attention. Bayer trimmed its year-end net financial debt guidance to €29–30 billion, down from a previous range of €32–33 billion, even as debt stood at €33.647 billion as of June 30. Two financing moves underpinned the improved outlook: Apollo Global Management injected €3 billion in equity, and Bayer placed $5 billion in bonds to refinance existing liabilities. CEO Bill Anderson reaffirmed the currency-adjusted full-year guidance, while the company quietly continues to evaluate a potential breakup into its agriculture, pharma, and consumer health units — though management stresses that operational performance and deleveraging remain the immediate priorities.
Should investors sell immediately? Or is it worth buying Bayer?
The market’s response was swift. Xetra trading on Wednesday saw the shares climb 3.23 percent following the earnings release, with the stock closing at €49.40 — a 2.28 percent gain on the day. The shares have now advanced 33.48 percent since the start of the year and sit roughly 8.3 percent below the 52-week high of €53.86 reached on July 3. By Thursday, the stock was changing hands around €49.62, up 0.45 percent on the session and 2.50 percent higher on the week.
The combination of a stronger legal position, a solid earnings beat, and a healthier capital structure has triggered a flurry of price-target revisions. Goldman Sachs lifted its target from €62.50 to €63.50 on Wednesday, maintaining a “Buy” rating. UBS followed the same day, raising its target more aggressively from €52 to €62, also with a “Buy” call — noting that operating results had beaten consensus estimates by 10 percent. DZ Bank analyst Peter Spengler weighed in on Thursday, bumping his fair value from €54 to €60 while reaffirming a buy recommendation. JPMorgan also raised its target, albeit more modestly.
On the operational front, Bayer is pressing ahead with digital initiatives in agriculture. The AI-powered pest-detection platform “MagicTrap 2,” designed for rapeseed cultivation, was rolled out to 14 additional European markets in July, including the UK. Meanwhile, the company has consolidated its US glyphosate business into a newly created standalone unit called Ruveon, a move intended to provide greater operational flexibility in a segment that remains legally sensitive.
Two dates now anchor the calendar for Bayer shareholders: September 10, when the Missouri court will hold the final hearing on the glyphosate settlement, and November 3, when third-quarter results are due. The intervening weeks will reveal whether the recent momentum — legal, operational, and financial — can be sustained.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from August 6 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 6.
Bayer: Buy or sell? Read more here...
